vs
BIODESIX INC（BDSX）与BioNexus Gene Lab Corp（BGLC）财务数据对比。点击上方公司名可切换其他公司
BIODESIX INC的季度营收约是BioNexus Gene Lab Corp的59.4倍（$28.8M vs $483.8K）。BIODESIX INC净利率更高（-13.8% vs -214.2%，领先200.3%）。BIODESIX INC同比增速更快（40.8% vs -80.8%）。BioNexus Gene Lab Corp自由现金流更多（$960.1K vs $692.0K）。过去两年BIODESIX INC的营收复合增速更高（39.3% vs -54.9%）
BIODESIX INC是一家专注于肿瘤与感染病领域的分子诊断企业，开发并商业化创新血液检测解决方案，主要服务北美地区的医疗机构、生物制药合作伙伴及患者，核心业务包括辅助临床决策的个性化医疗产品。
BioNexus Gene Lab Corp是一家生物技术企业，主营分子诊断检测、基因分析及相关生命科学解决方案，服务客户涵盖医疗机构、科研机构及个人用户，核心市场主要覆盖东南亚地区。
BDSX vs BGLC — 直观对比
营收规模更大
BDSX
是对方的59.4倍
$483.8K
营收增速更快
BDSX
高出121.6%
-80.8%
净利率更高
BDSX
高出200.3%
-214.2%
自由现金流更多
BGLC
多$268.1K
$692.0K
两年增速更快
BDSX
近两年复合增速
-54.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $28.8M | $483.8K |
| 净利润 | $-4.0M | $-1.0M |
| 毛利率 | — | -0.8% |
| 营业利润率 | -6.8% | -213.5% |
| 净利率 | -13.8% | -214.2% |
| 营收同比 | 40.8% | -80.8% |
| 净利润同比 | 51.8% | -197.5% |
| 每股收益（稀释后） | $-3.35 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDSXBGLC
| Q4 25 | $28.8M | $483.8K | ||
| Q3 25 | $21.8M | $2.5M | ||
| Q2 25 | $20.0M | $2.3M | ||
| Q1 25 | $18.0M | $2.1M | ||
| Q4 24 | $20.4M | $2.5M | ||
| Q3 24 | $18.2M | $2.6M | ||
| Q2 24 | $17.9M | $2.0M | ||
| Q1 24 | $14.8M | $2.4M |
净利润BDSXBGLC
| Q4 25 | $-4.0M | $-1.0M | ||
| Q3 25 | $-8.7M | $-709.0K | ||
| Q2 25 | $-11.5M | $-616.2K | ||
| Q1 25 | $-11.1M | $-623.3K | ||
| Q4 24 | $-8.3M | $-348.3K | ||
| Q3 24 | $-10.3M | $-1.3M | ||
| Q2 24 | $-10.8M | $199.1K | ||
| Q1 24 | $-13.6M | $-103.8K |
毛利率BDSXBGLC
| Q4 25 | — | -0.8% | ||
| Q3 25 | — | 14.8% | ||
| Q2 25 | — | 16.3% | ||
| Q1 25 | — | 16.1% | ||
| Q4 24 | — | 12.3% | ||
| Q3 24 | — | 12.4% | ||
| Q2 24 | — | 14.6% | ||
| Q1 24 | — | 15.3% |
营业利润率BDSXBGLC
| Q4 25 | -6.8% | -213.5% | ||
| Q3 25 | -32.4% | -27.6% | ||
| Q2 25 | -48.6% | -27.0% | ||
| Q1 25 | -50.9% | -28.9% | ||
| Q4 24 | -32.5% | -16.5% | ||
| Q3 24 | -47.3% | -50.9% | ||
| Q2 24 | -46.0% | 13.1% | ||
| Q1 24 | -74.4% | -3.3% |
净利率BDSXBGLC
| Q4 25 | -13.8% | -214.2% | ||
| Q3 25 | -40.0% | -27.9% | ||
| Q2 25 | -57.3% | -27.3% | ||
| Q1 25 | -61.8% | -29.2% | ||
| Q4 24 | -40.4% | -13.8% | ||
| Q3 24 | -56.5% | -51.1% | ||
| Q2 24 | -60.3% | 10.1% | ||
| Q1 24 | -91.9% | -4.4% |
每股收益（稀释后）BDSXBGLC
| Q4 25 | $-3.35 | — | ||
| Q3 25 | $-1.16 | $-0.40 | ||
| Q2 25 | $-0.08 | $-0.34 | ||
| Q1 25 | $-0.08 | $-0.04 | ||
| Q4 24 | $-5.02 | $0.55 | ||
| Q3 24 | $-1.40 | $-0.75 | ||
| Q2 24 | $-0.08 | $0.11 | ||
| Q1 24 | $-0.14 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.0M | $2.5M |
| 总债务越低越好 | $50.0M | — |
| 股东权益账面价值 | $-2.5M | $8.6M |
| 总资产 | $87.5M | $9.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDSXBGLC
| Q4 25 | $19.0M | $2.5M | ||
| Q3 25 | $16.6M | — | ||
| Q2 25 | $20.7M | — | ||
| Q1 25 | $17.6M | — | ||
| Q4 24 | $26.2M | $2.9M | ||
| Q3 24 | $31.4M | — | ||
| Q2 24 | $42.2M | — | ||
| Q1 24 | $11.5M | — |
总债务BDSXBGLC
| Q4 25 | $50.0M | — | ||
| Q3 25 | $50.0M | — | ||
| Q2 25 | $50.0M | — | ||
| Q1 25 | $40.0M | — | ||
| Q4 24 | $40.0M | — | ||
| Q3 24 | $40.0M | — | ||
| Q2 24 | $40.1M | — | ||
| Q1 24 | $40.1M | — |
股东权益BDSXBGLC
| Q4 25 | $-2.5M | $8.6M | ||
| Q3 25 | $-1.7M | $6.8M | ||
| Q2 25 | $1.1M | $7.5M | ||
| Q1 25 | $11.1M | $7.8M | ||
| Q4 24 | $20.9M | $8.3M | ||
| Q3 24 | $27.9M | $9.4M | ||
| Q2 24 | $36.3M | $9.5M | ||
| Q1 24 | $-5.5M | $9.3M |
总资产BDSXBGLC
| Q4 25 | $87.5M | $9.3M | ||
| Q3 25 | $88.7M | $7.6M | ||
| Q2 25 | $87.7M | $9.4M | ||
| Q1 25 | $86.2M | $9.5M | ||
| Q4 24 | $97.2M | $10.4M | ||
| Q3 24 | $102.7M | $11.0M | ||
| Q2 24 | $115.8M | $11.1M | ||
| Q1 24 | $87.2M | $11.2M |
负债/权益比BDSXBGLC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 43.95× | — | ||
| Q1 25 | 3.62× | — | ||
| Q4 24 | 1.92× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $778.0K | $961.1K |
| 自由现金流经营现金流 - 资本支出 | $692.0K | $960.1K |
| 自由现金流率自由现金流/营收 | 2.4% | 198.5% |
| 资本支出强度资本支出/营收 | 0.3% | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-23.5M | $-1.9M |
8季度趋势，按日历期对齐
经营现金流BDSXBGLC
| Q4 25 | $778.0K | $961.1K | ||
| Q3 25 | $-8.9M | $-1.2M | ||
| Q2 25 | $-6.6M | $-737.9K | ||
| Q1 25 | $-8.6M | $-824.1K | ||
| Q4 24 | $-4.1M | $219.2K | ||
| Q3 24 | $-10.7M | $-1.6M | ||
| Q2 24 | $-18.6M | $-672.3K | ||
| Q1 24 | $-15.3M | $-37.2K |
自由现金流BDSXBGLC
| Q4 25 | $692.0K | $960.1K | ||
| Q3 25 | $-8.9M | $-1.2M | ||
| Q2 25 | $-6.6M | $-759.4K | ||
| Q1 25 | $-8.7M | $-833.1K | ||
| Q4 24 | $-4.9M | $215.2K | ||
| Q3 24 | $-10.9M | $-1.8M | ||
| Q2 24 | $-20.5M | $-674.1K | ||
| Q1 24 | $-15.5M | $-59.1K |
自由现金流率BDSXBGLC
| Q4 25 | 2.4% | 198.5% | ||
| Q3 25 | -41.0% | -48.9% | ||
| Q2 25 | -33.1% | -33.6% | ||
| Q1 25 | -48.3% | -39.0% | ||
| Q4 24 | -24.2% | 8.5% | ||
| Q3 24 | -60.1% | -68.5% | ||
| Q2 24 | -114.3% | -34.1% | ||
| Q1 24 | -104.9% | -2.5% |
资本支出强度BDSXBGLC
| Q4 25 | 0.3% | 0.2% | ||
| Q3 25 | 0.2% | 0.2% | ||
| Q2 25 | 0.3% | 0.9% | ||
| Q1 25 | 0.4% | 0.4% | ||
| Q4 24 | 4.1% | 0.2% | ||
| Q3 24 | 1.3% | 7.6% | ||
| Q2 24 | 10.7% | 0.1% | ||
| Q1 24 | 1.6% | 0.9% |
现金转化率BDSXBGLC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -3.38× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDSX
| Diagnostic Tests | $25.1M | 87% |
| Development Services | $3.6M | 13% |
BGLC
暂无分部数据
